History repeating: guidelines to address common problems in psychedelic science
Therapeutic Advances in Psychopharmacology, vol. 13, pp. 20451253231198466
Abstract
Research in the last decade has expressed considerable optimism about the clinical potential of psychedelics for the treatment of mental disorders. This optimism is reflected in an increase in research papers, investments by pharmaceutical companies, patents, media coverage, as well as political and legislative changes. However, psychedelic science is facing serious challenges that threaten the validity of core findings and raise doubt regarding clinical efficacy and safety. In this paper, we introduce the 10 most pressing challenges, grouped into easy, moderate, and hard problems. We show how these problems threaten internal validity (treatment effects are due to factors unrelated to the treatment), external validity (lack of generalizability), construct validity (unclear working mechanism), or statistical conclusion validity (conclusions do not follow from the data and methods). These problems tend to co-occur in psychedelic studies, limiting conclusions that can be drawn about the safety and efficacy of psychedelic therapy. We provide a roadmap for tackling these challenges and share a checklist that researchers, journalists, funders, policymakers, and other stakeholders can use to assess the quality of psychedelic science. Addressing today's problems is necessary to find out whether the optimism regarding the therapeutic potential of psychedelics has been warranted and to avoid history repeating itself.
Authors 2
-
Michiel van Elk corresponding Aachen Cognitive Psychology Unit Institute of Psychology, Leiden University
Affiliation as printed
Cognitive Psychology Unit, Institute of Psychology, Leiden University, PO Box 9555, Leiden 2300 RB, The Netherlands
-
Affiliation as printed
Clinical Psychology Unit, Institute of Psychology, Leiden University, Leiden, The Netherlands
Cited by 131 stored of 131
Cited by patents worldwide 2 (Lens.org)
-
Aerosol comprising 5-methoxy-N,N-dimethyltryptamineUS12685721B2 2026-07-21 Active
-
Recrystallisation of 5-methoxy-N,N-dimethyltryptamine(5-MeO-DMT)US12612363B2 2026-04-28 Active